Jubilant Ingrevia Limited Business Intelligence Report
Jubilant Ingrevia Limited Business Intelligence Report
Quality Scores
Latest Quarterly Earnings Summary
No quarterly summary available yet.
AI Summary
Jubilant Ingrevia, spun off from Jubilant Life Sciences, is a vertically integrated specialty chemicals player with leadership in Pyridine, Vitamin B3, and Acetic Anhydride. The company serves global giants in pharma and agrochemicals, leveraging a low-cost manufacturing base. While the legacy business is 40 years old, as a standalone entity since 2021, it has faced significant margin compression from cyclical highs. Revenue has stagnated around ₹4,100-4,700 Cr, reflecting volatility in commodity chemical prices despite growth in specialty segments. The investment thesis hinges on a…
Key Changes in FY2026
The business has evolved significantly from a legacy chemical manufacturer to a global 'Innovative Solutions' provider serving elite global Pharma and Agrochemical companies. Over the last five years, the portfolio has expanded beyond basic chemicals into specialized Pyridine derivatives and CDMO services, where it now serves 15 of the top 20 global pharma firms. The strategic shift is evident in the Capex cycle, moving from ₹1,805 Cr in Fixed Assets (2021) to ₹3,183 Cr (2026), reflecting a deep commitment to high-value product segments and capacity expansion. Despite cyclical headwinds in 2023-2024 that saw sales contract, the business recovered with a focus on low-cost leadership and premiumization of the product mix. The transition toward renewable power (evidenced by the ESG focus in…
Management Commentary
Management demonstrates deep domain expertise with a 40-year legacy in the chemical value chain. Transparency is high with regular earnings calls and detailed investor presentations, though communication on the exact timing of margin recovery has been optimistic. Strategic intent is clearly focused on moving up the value chain toward 'Innovative Solutions' to reduce cyclicality. There is a clear alignment with global ESG and quality standards required by Tier-1 pharma clients. However, the recent reduction in promoter holding (-6.25% over 3 years) is a monitorable that requires explanation.
Financial Highlights
The financial profile is characterized by high initial profitability in Mar 2022 (17% OPM) which has since normalized to 10-13% levels. Revenue growth is currently weak with a 3-year CAGR of -3%, primarily due to pricing headwinds in life science chemicals. While the company maintains a decent return on equity (currently ~10%), it is significantly lower than its peak of 29%. Operating profits have declined from ₹841 Cr in 2022 to ₹567 Cr projected for 2026, though a recovery trend is visible in recent quarters. The balance sheet has expanded through debt-funded capex, with borrowings rising from ₹238 Cr to nearly ₹800 Cr over four years.
Major Opportunities
- Global leadership in Pyridine + Beta and Vitamin B3
- Strong client list including 15 of top 20 Global Pharma
- Reduction in Working Capital Days from 29.4 to 22.0
Major Risks
- Declining Operating margins (17% to 10%)
- Promoter holding decreased by 6.25%
- Low ROE of 8.48% over the last 3 years
About Jubilant Ingrevia Limited's Annual Report & Financial Performance
The latest Jubilant Ingrevia Limited annual report (FY2026) is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.
What this Jubilant Ingrevia Limited research covers
- Fundamental & business analysis
- Financial statements & performance
- Management commentary & discussion
- Corporate governance & auditor report
- Cash flow analysis & capital allocation
- Valuation analysis & business quality
- Growth analysis & competitive position
- Risk, SWOT & moat analysis
- Quarterly earnings & conference-call summary
- Sector, industry & peer comparison
- Latest official company filings
- Business outlook & long-term growth
Jubilant Ingrevia Limited — Frequently Asked Questions
Explore more Jubilant Ingrevia Limited research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.